Disease

Laryngeal Neoplasms

Late-stage therapeutic developmentEmerging research

MeSHLaryngeal Neoplasms

Publications

Clinical trials

2003

Latest publication

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.

Research2003-11-01The New England journal of medicine

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low

Key developments

1 clinical trial expected to report results, the earliest in Q4 2029.

Upcoming Milestones

Q4 2029DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

Major developments

Upcoming trial readoutImportant

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

Results expected Q4 20292025-11-24

Clinical Milestones1View

Results expected 1

2025-11-24DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.Results expected Q4 2029

Activity timeline1

2025-11-24ClinicalDETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.Results expected Q4 2029

Clinical trials

7 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme

All trials

Active

Late-stage

Completed

Late-stage studies

Phase 2/3 · Recruiting · Cancer Research UK

Recruiting

Phase 2/3 · Recruiting · Cancer Research UK

ELOS - Induction Chemotherapy With Docetaxel and Cisplatin Followed by Radiation Compared to Additional PD-1 Inhibition in CPS ≥1 Advanced Laryngeal/Hypopharyngeal Cancer Suitable for Laryngectomy Selected After Early Response Evaluation

Phase 2 · Recruiting · University of Leipzig

Recently completed

A Novel Robotic System for Single Port and Natural Orifice Transluminal Endoscopic Surgery: A Prospective, Single Center, Multispecialty Study

N/A · Completed · Chinese University of Hong Kong

Organ Preservation: Weekly Carboplatin & Taxol w/Concurrent RT for Locally Advanced Laryngeal & Hypopharyngeal CA

N/A · Completed · King Faisal Specialist Hospital & Research Center

F-18 Fluorothymidine (FLT) PET Imaging for Early Evaluation of Response to Chemoradiation Therapy in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 2 · Completed · University of Iowa

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.

The New England journal of medicine · 2003 · 2,008 cites

Recent publications

Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.

The New England journal of medicine · 2003 · 2,008 cites

Leading journals1

The New England journal of medicine1

Leading researchers8

Chao C1
Cooper J1
Ensley J1
Forastiere AA1
Glisson B1
Goepfert H1
Leaf A1
Lee DJ1

Affiliations (unnormalised)1

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.

Identifiers

MeSHLaryngeal Neoplasms

References & data sources

Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
Related entities are derived from literature co-mention (studied together) — associative, not causal.